Passage Bio amends merger terms: what it means for Passage Bio stock

Passage Bio (ISIN US7027122099) has amended the terms of its proposed merger with Remix Therapeutics, with stockholders set to vote on the transaction on November 5, 2026. The filing sets the structure, financing threshold and ownership split that will determine the combined company's starting position.

What changed on October 5

According to StockTitan, Passage Bio filed an amendment to its Form S-4 on October 5, 2026. The proposed concurrent financing combines USD 70.0 million from common stock and pre-funded warrant sales with USD 30.0 million of convertible promissory notes, for expected gross proceeds of USD 100.0 million.

The merger can close only if Remix receives at least USD 99,929,000 in concurrent-financing cash proceeds, subject to written waivers. The filing also says the assumed exchange ratio is 0.1727 Passage Bio shares for each Remix share, while the concurrent-financing exchange ratio is assumed at 0.1728.

What does the financing mean?

Under the filing's fully diluted assumptions, Remix pre-merger holders would own 65.00 percent of the combined company, financing investors 29.00 percent and existing Passage Bio holders 6.00 percent. Those percentages can change with the final net-cash figure and other closing adjustments.

Three steps toward the vote

On June 24, 2026, Passage Bio and Remix entered their original merger agreement alongside an initial USD 70.0 million subscription financing, according to StockTitan. On September 2, 2026, the companies signed an amended and restated merger agreement with the 0.1727 assumed exchange ratio. On October 5, 2026, the S-4 amendment documented the USD 99,929,000 closing condition and the projected 6.00 percent ownership for Passage Bio holders.

Next date for shareholders

The next stated corporate date is November 5, 2026, when Passage Bio stockholders are scheduled to vote on the share issuance, the proposed reverse split and the charter changes. The reverse split proposal covers a range from 1-for-2 to 1-for-10, while the proposed name change would create Remix Therapeutics, Inc.

Clinical platform remains central

Passage Bio describes itself as a clinical-stage genetic medicines company focused on neurodegenerative diseases. Its lead candidate PBFT02 is designed to raise progranulin levels in frontotemporal dementia, while its wider pipeline includes programs for GM1 gangliosidosis, Krabbe disease and metachromatic leukodystrophy, according to the Passage Bio investor overview.

Transaction terms drive the outlook

The November vote is therefore the immediate decision point for the proposed combination, while the USD 100.0 million financing and the 6.00 percent projected ownership give investors the clearest numerical framework for assessing the deal.

Market context: Market report Nasdaq Composite.

More news and analyses on Passage Bio stock